The Held-Load Sequence: A Clinical Model of How Women's Hearts Are Lost

Dr. Job Mogire, MD, FACP, FACC Board-Certified Cardiologist | Carle Foundation Hospital, Champaign, IL

Women don’t die from what they have. Women die from what they hold.

That is the thesis of this entire wing, and the Held-Load Sequence is its clinical form. The sequence is a model, a way of connecting findings that are usually studied in isolation into a single chain that explains how a woman who looks fine ends up with a cardiac event recognized too late. The chain as a whole is a conceptual synthesis. Each link within it is rated for the evidence behind it, and the chain is never asserted beyond what its links support.

The chain

Sustained role and caregiving overload, the carried weight. 3 / Early A life organized around carrying others, at home and at work, with the self placed last. This opening link is sociological and rated accordingly.

Chronic sympathetic activation and allostatic load. 4 / Promising Sustained demand without recovery keeps the stress systems switched on, producing the cumulative biological wear captured by the allostatic-load framework.

HPA axis dysregulation, sex-specific cortisol patterning. 3 / Early Chronic activation disturbs the body’s cortisol rhythm, with patterns that differ by sex. The mechanism is plausible and still developing.

Symptom minimization and care deferral, “I’m fine.” 3 / Early The carried weight expresses itself as deferral: symptoms downplayed, care postponed, the self triaged last. Behavioral, and rated as such.

Endothelial and coronary microvascular dysfunction. 4 / Promising The first measurable cardiac link: women’s small-vessel disease, non-obstructive, the kind the angiogram cannot see, documented in the WISE program.

The reproductive risk amplifiers stack. 4 / Promising Prior preeclampsia, gestational diabetes, preterm birth, early menopause, PCOS, and autoimmune disease accumulate as recognized risk enhancers, the reproductive risk stack.

Estrogen withdrawal at menopause removes vascular protection. 4 / Promising Across the menopause transition, ApoB and LDL rise, blood pressure rises, and visceral fat redistributes. This link is mechanism: it describes why risk rises, and it does not imply that hormone therapy prevents cardiovascular disease, which the evidence does not support.

Presentation read as anxiety, not cardiac, the dismissal. 3 / Early When the woman finally presents, a male-derived heuristic reads her symptoms as anxiety, the Yentl pattern.

Diagnostic delay. 4 / Promising The delay resolves into MINOCA, INOCA, Takotsubo, or under-treated obstructive disease.

Cardiac event, recognized late, treated less, outcome worse. 4 / Promising The endpoint the whole chain bends toward.

How the model is used

The sequence is diagnostic, not deterministic. 3 / Early No woman is fated to travel the whole chain, and the value of the model is that it identifies where she is on it and where intervention breaks the progression: reducing the load, restoring recovery, naming the non-obstructive disease through coronary function testing, counting the reproductive stack, measuring through the menopause transition, and refusing the anxiety default. Each link is also an exit.

The evidence behind allostatic load

The concept of allostatic load was introduced by McEwen and Stellar in a 1993 paper in Science describing how the body achieves stability through change, a process they named allostasis. The cost of repeated or sustained allostatic responses, paid in physiological wear across neuroendocrine, immune, metabolic, and cardiovascular systems, became the allostatic load. The framework was not a metaphor. McEwen and colleagues built a composite score from measurable biomarkers: cortisol, epinephrine, norepinephrine, DHEA-S, blood pressure, waist-to-hip ratio, HDL cholesterol, total cholesterol, glycated hemoglobin, and fibrinogen. A woman accumulating scores on these measures is not experiencing stress in any abstract sense. She is accumulating documented physiological dysregulation.

The question of whether sustained occupational and role demand specifically predicts cardiac outcomes was addressed in the Whitehall II study, a large British cohort study of civil servants. Whitehall II found that low job control, the structural condition of working hard without the authority to shape that work, independently predicted incident coronary heart disease, even after controlling for conventional risk factors. The relevance to the Held-Load Sequence is specific: the opening link in the chain is not about subjective distress. It is about objective structural conditions that produce sustained sympathetic activation without the recovery that would permit allostatic reset. Women in high-demand, low-control roles, including the domestic caregiving role that most standard occupational analyses do not capture, are in exactly this position.

Sex differences in allostatic load accumulation are documented, though the mechanisms behind them are still being characterized. Women accumulate higher composite allostatic load scores in several studied populations, and the specific biomarker profiles differ by sex. Men show greater cardiovascular and metabolic dysregulation; women show more HPA axis and immune dysregulation. This is not a minor distinction. It means the downstream disease pathway differs by sex, with implications for which tests will find the damage and which will miss it.

Endothelial dysfunction: the physiological bridge

Chronic sympathetic activation produces its cardiac damage through a specific biological bridge: endothelial dysfunction. The endothelium is the single-cell layer lining every blood vessel in the body. In a healthy state, it produces nitric oxide, which relaxes vascular smooth muscle, keeps blood flow appropriate to demand, and suppresses inflammation and clotting. Cortisol, the end product of sustained HPA axis activation, interferes with this system at multiple points. It reduces the expression of endothelial nitric oxide synthase, the enzyme that makes nitric oxide, and it promotes the expression of adhesion molecules that allow inflammatory cells to stick to the vessel wall. The result is a vessel that cannot dilate appropriately, that cannot suppress inflammation, and that is primed for plaque formation and instability.

This mechanism is not speculative. Endothelial dysfunction is measurable, through flow-mediated dilation of the brachial artery, through coronary reactivity testing, and through circulating biomarkers. The WISE program, the Women’s Ischemia Syndrome Evaluation, was the first large study designed specifically to characterize ischemic heart disease in women, and its central finding was that women with chest pain and signs of ischemia on stress testing frequently had normal or near-normal coronary angiograms. This was not reassuring. Subsequent follow-up in the WISE cohort showed that these women had worse outcomes than initially assumed: elevated rates of major adverse cardiac events, hospitalizations, and persistent functional limitation. The mechanism was endothelial and microvascular dysfunction, not obstructive plaque, and the standard angiogram was simply not measuring it.

The chronic sympathetic activation that sustained load produces does exactly what the WISE data would predict: it degrades the endothelium in ways that are expressed through the microvasculature rather than through large-vessel obstruction, producing the disease pattern that women disproportionately carry.

Coronary microvascular dysfunction in depth

Coronary microvascular dysfunction and its symptomatic correlate, ischemia with non-obstructive coronary arteries (INOCA), are not diagnoses of exclusion. They are diagnoses of mechanism, and they require specific testing to establish.

The microvasculature, the vessels below the resolution of angiography, regulates flow through two mechanisms that can fail independently. The first is vasodilation capacity: when demand increases, small vessels normally dilate to increase flow, a capacity measured as coronary flow reserve (CFR). A CFR below 2.0 is abnormal; values below 2.5 are considered reduced. Women with chest pain and normal coronary arteries have documented reductions in CFR across multiple studies. The second mechanism is microvascular spasm: inappropriate vasoconstriction in the small vessels, separate from the epicardial spasm that produces variant angina and that is more common in younger women.

The WISE program’s longitudinal data showed that women with reduced CFR and normal coronary arteries had an annual major adverse cardiac event rate significantly above zero. In one WISE analysis, women with CFR below 2.32 had a substantially higher rate of adverse outcomes over a five-year follow-up than women with preserved CFR, even though their angiograms appeared normal. This overturned the clinical assumption that a normal angiogram was functionally equivalent to a normal risk assessment.

The clinical implication is specific: the diagnostic workup in a woman with chest pain, exertional symptoms, or ischemia on stress testing cannot stop at the angiogram. Coronary reactivity testing, administering acetylcholine or adenosine directly into the coronary artery to assess both epicardial and microvascular response, is the gold standard for characterizing INOCA. It is available at specialized centers and is underused. A woman who has been told “your arteries look clean” may have received half a diagnosis.

INOCA also overlaps with Takotsubo cardiomyopathy, the stress-triggered syndrome in which the left ventricle balloons acutely, predominantly in postmenopausal women, in response to physical or emotional shock. Takotsubo is not a benign self-limiting event in all cases: in-hospital mortality and recurrence rates are measurable. Its mechanism involves catecholamine surge, microvascular dysfunction, and estrogen loss, all nodes already on the Held-Load Sequence chain.

The menopause vascular biology link

Estrogen’s vascular protection is not folklore. It is mechanism, and the loss of it at menopause is a documented physiological event with cardiac consequences.

Estrogen acts on the endothelium through estrogen receptors expressed on endothelial cells. Binding activates endothelial nitric oxide synthase directly, increasing nitric oxide production and maintaining vasodilation. Estrogen also suppresses the expression of vascular cell adhesion molecules, reducing the inflammatory cell recruitment that initiates plaque formation. It modulates LDL oxidation and shifts the lipid profile toward smaller LDL particle size and higher HDL. At the level of vascular smooth muscle, estrogen promotes the calcium channel dynamics that favor relaxation over spasm.

When estrogen falls at menopause, each of these effects reverses. Nitric oxide production falls. Adhesion molecule expression rises. LDL rises, ApoB rises, and the LDL particles shift toward the smaller, denser phenotype that penetrates the vessel wall more easily. Blood pressure rises, driven partly by aldosterone and angiotensin II no longer modulated by estrogen. Visceral fat accumulates, bringing its own inflammatory and metabolic consequences.

The timing of this transition matters. The menopause transition, perimenopause, is not a discrete event. It can extend over several years, during which estrogen fluctuates before declining. Cardiovascular risk markers rise during this period, not uniformly after it. The Study of Women’s Health Across the Nation (SWAN), a multi-site longitudinal cohort, documented rising LDL, rising blood pressure, and rising inflammatory markers across the menopause transition in a large and demographically diverse sample. A woman entering perimenopause in her mid-forties who is not being followed for these changes may accumulate several years of rising risk before anyone measures it.

This link in the chain does not support hormone therapy as cardiac prevention. The Women’s Health Initiative data, and subsequent analyses, do not support initiating estrogen for the purpose of reducing cardiovascular risk, particularly in older postmenopausal women. The mechanism of estrogen’s protection is real; the clinical strategy of replacing it to prevent cardiac events is not supported. What is supported is measuring the woman who is moving through this transition: lipids, blood pressure, fasting glucose, and inflammatory markers, and intervening on what is found, not on the estrogen itself.

Where you are on the chain: the clinical conversation

The Held-Load Sequence maps to a specific conversation, one that most women have never had with a cardiologist because the cardiologist is rarely asked to think about load, cortisol patterning, or reproductive history as cardiac data.

If you are bringing this model to a clinical visit, these are the questions and tests that correspond to each node.

The load node corresponds to a structured conversation about role demand: how many people depend on you, what recovery looks like in your week, whether sleep is restorative or interrupted, whether you have had sustained periods without a genuine decompression. This is not a wellness questionnaire. It is the clinical input that determines whether chronic sympathetic activation is structurally likely.

The stress physiology node corresponds to measurable biomarkers. A high-sensitivity C-reactive protein reflects chronic low-grade inflammation downstream of sympathetic and HPA activation. Fasting cortisol is a rough screen; a 24-hour urinary cortisol collection is more informative. Heart rate variability, measurable from a wearable device over several days, reflects the ratio of sympathetic to parasympathetic tone and is reduced in chronic sympathetic overdrive.

The endothelial dysfunction node corresponds to brachial artery flow-mediated dilation, a non-invasive vascular study, or to coronary reactivity testing if chest pain or ischemia is already established. Not every woman needs invasive testing. A woman with exertional chest discomfort, dyspnea, or a positive stress test and a normal angiogram does.

The reproductive risk stack node is a history, not a test. Ask your clinician whether your prior preeclampsia, gestational diabetes, preterm delivery, PCOS diagnosis, or early menopause before age 45 is in your cardiac risk assessment. These are recognized cardiovascular risk enhancers in the 2019 ACC/AHA guidelines. If they are not in your record as cardiac risk data, they are missing from your risk estimate.

The menopause node corresponds to a transition-period lipid panel, blood pressure measurement, and fasting glucose, done during perimenopause, not after it. If you are in your mid-forties and experiencing cycle irregularity, this is the moment to measure, not to wait.

The dismissal node is the one you have to name yourself. If a prior evaluation attributed your symptoms to anxiety, deconditioning, or stress without completing a non-obstructive disease workup, that evaluation may have stopped at the wrong diagnostic endpoint. A second opinion from a cardiologist with expertise in women’s cardiac disease is appropriate.

What this means

The Held-Load Sequence is the clinical model behind a single sentence: women die from what they hold. It chains sustained load, stress physiology, non-obstructive disease, the reproductive risk stack, the menopause shift, and the dismissal into the late-recognized event that ends too many women’s lives, with each link held to its evidence. Its two women-specific nodes, non-obstructive disease and the reproductive stack, are exactly what a male-derived model omits. Seeing the chain is how a woman, and her clinician, learn where to break it.